Abbott follows rival Dexcom with OTC glucose monitor launch in US
Adds details on the device in paragraph 3, background in paragraphs 6-7
By Sneha S K
Sept 5 (Reuters) -Abbott ABT.N has launched its over-the-counter continuous glucose monitoring system in the U.S., the company said on Thursday, making it the second such device on the market to help people track their blood sugar levels.
The device, called Lingo, will compete with a rival from DexCom DXCM.O, launched last week, and will be available for adults who are not on insulin.
Continuous glucose monitors are already multi-billion dollar products due to demand from diabetes patients, and companies are looking to expand the market by targeting health-conscious customers.
"There is a great deal of interest in tracking biomarkers that provide insights into one's health and wellness that were previously undetectable using the trackers available to consumers," said Olivier Ropars, the head of Abbott's Lingo business.
A continuous glucose monitoring system consists of coin-sized adhesive skin patches with a Bluetooth link to a smartphone, versus drawing blood through a finger stick.
The readings help determine whether diabetic patients need an insulin dose.
Lingo is available for consumers 18 years and older not on insulin in three payment options - $49 for two weeks, $89 for four weeks and $249 for 12 weeks, the company said on Thursday. Each biosensor can be worn for up to two weeks.
Dexcom's Stelo is available at a price of up to $99 for two sensors. It is also available at $89 for a four-week subscription.
Abbott received the U.S. health regulator's clearance for Lingo, available in Britain since January for 120-150 pounds ($152-$190) per month, in June.
Abbott's CEO Robert Ford said in July that the company would use a mix of TV advertisements and guerilla marketing to tap people without diabetes for the U.S. launch.
Reporting by Sneha S K; Editing by Janane Venkatraman and Sriraj Kalluvila
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
